More recently, PARP moved into the spotlight with the discovery that PARP inhibition in both cancer cell lines (2, 24) and human tumors (25) lacking BRCA1 or BRCA2 is selectively cytotoxic compared to non-mutation containing tumors. The gene discussed is BRCA1; the disease is cancer.